Navigation Links
Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival

and thrombocytopenia (each 3%).

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Millennium's website is www.millennium.com.

This press release contains "forward-looking statements," including statements about the Company's growth and development of products. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company's dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to c
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
2. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
3. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:11/26/2014)... Mass. , Nov. 25, 2014 Reinforcing ... Royal Philips (NYSE: PHG AEX: ... and Drug Administration (FDA) for its IQon Spectral ... imaging. This first-of-its kind technology adds a new dimension ... offering the ability to characterize structures based on their ...
(Date:11/26/2014)... 2014   Heska Corporation (NASDAQ: HSKA ... provider of advanced veterinary diagnostic and other specialty veterinary ... Chair, will attend The Benchmark Company, LLC,s Micro Cap Discovery ... be held at The Palmer House Hilton, 17 E. Monroe ... to 2:30 p.m. Please email hska@haydenir.com or contact ...
(Date:11/26/2014)... BOCA RATON, Fla. , Nov. 25, 2014 ... has entered into a multi-product ANDA agreement with ... Maryland ) under which Breckenridge and Pii ...  Under the terms of the agreement, Pii will ... will market and distribute the products under its ...
Breaking Medicine Technology:Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3Heska to Attend Benchmark Micro Cap Discovery Conference 2Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2
... 1 Older adults who exercise regularly show increased cerebral blood flow ... to findings presented today at the annual meeting of the Radiological Society ... The study, conducted at the University of North Carolina ( ... of older adults who exercise to brain scans of those who do ...
... New study finds the majority of acute lymphoblastic leukemia relapse ... of diagnosis , , MEMPHIS, ... Hospital have identified distinctive genetic changes in the cancer cells ... The finding offers a pathway to designing treatments for ALL ...
Cached Medicine Technology:Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3
(Date:11/27/2014)... Luciana Lagana and her husband ... Omadox, a feature film that received 9 awards at the ... ensemble cast. It is also an official selection of the ... a successful cinematic career for James Noel, a young filmmaker ... enjoy experimental mystery, filmed in glorious black and white, watching ...
(Date:11/27/2014)... 27, 2014 Blood-borne pathogens raise the ... precautions and procedures in place to counter this. However, ... of things tainted with menstrual blood are taken as ... simpler, more sanitary way to handle tampons and menstrual ... from Sonora, Calif. , He then created a prototype ...
(Date:11/27/2014)... 27, 2014 Nearly 1,100 Risperdal ... in a consolidated litigation now underway in Pennsylvania ... Documents recently updated in the Philadelphia Court of ... state proceeding, all of which involve a drug ... psychiatric conditions. Many of the cases in this ...
(Date:11/27/2014)... By Dennis Thompson ... -- An experimental Ebola vaccine appears to be safe and ... the deadly virus, according to early clinical trial results reported ... of the phase I clinical trial for the vaccine paves ... nations of Liberia and Sierra Leone as early as January, ...
(Date:11/27/2014)... The founders of VIM & VIGR, a ... functioning compression socks, are proud to announce the debut of ... Gradient Pressure (TM) knitting technology that is designed to increase ... commitment to adding flair and style to a product that ... the eye of a writer at The New York ...
Breaking Medicine News(10 mins):Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2
... Sciences Corporation announced,today a new initiative that ... instruments used in medical practice and healthcare,2.0 ... draws upon the,cognitive and anthropologic sciences, is ... human intelligence,s reliance on,narrative for richly conveying ...
... Build Healthy Communities, VICTORVILLE, Calif., April 16 ... Victorville Earth Day Eco Tote giveaway.,On Tuesday, April ... will be handing out recyclable Eco Totes to ... Reduce, Reuse, Recycle program, Heritage Victor Valley,Medical Group ...
... have discovered sleep patterns in a type of anesthesia ... snooze. , The anesthetic used in the study, known ... tool to more thoroughly investigate ways of treating sleep ... one of the studys co-authors and an associate professor ...
... AFL ) announced today that it will ... on April 23, 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20041202/CLTH019LOGO ... release, Aflac Incorporated will,webcast a conference call scheduled ... the teleconference, Aflac Incorporated Chairman and CEO Dan ...
... middle could be making us hungrier, so we eat more, ... Dr. Yaiping Yang and his colleagues at the Lawson Health ... abdominal fat tissue can reproduce a hormone that stimulates fat ... in the way we think about and treat abdominal obesity. ...
... Management Program improves patient care while ... saving ... of its inaugural Best Practices in Consumer Empowerment and,Protection Awards ... NeuroScience, Inc. and Eli Lilly,and Company as Silver Award winners ...
Cached Medicine News:Health News:IC Sciences Investigates Application of Narrative Sciences for Medical Informatics Instruments 2Health News:IC Sciences Investigates Application of Narrative Sciences for Medical Informatics Instruments 3Health News:Aflac Incorporated To Release First Quarter Results on April 23, 2008 2Health News:Your belly fat could be making you hungrier 2Health News:Mental Health Prescription Program Named Winner in URAC's Best Practices in Consumer Empowerment and Protection Awards 2Health News:Mental Health Prescription Program Named Winner in URAC's Best Practices in Consumer Empowerment and Protection Awards 3Health News:Mental Health Prescription Program Named Winner in URAC's Best Practices in Consumer Empowerment and Protection Awards 4